U-AZN

Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - http://www.astrazeneca.com

12:35:49 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
AZN - Q	0.2	75.26	·	75.28	0.1	75.27	+0.24	0.3	3,137.0	229,354	18,008	75.00 75.27 74.59	75.75 60.47	12:18:01	Apr 25	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 18008

More trades...

Time ET	Ex	Price	Change	Volume
12:18:05	Q	75.275	0.245	11
12:18:05	Q	75.275	0.245	89
12:18:05	Q	75.2721	0.2421	27
12:18:03	Q	75.27	0.24	100
12:18:01	Q	75.2758	0.2458	49
12:18:01	Q	75.27	0.24	100
12:17:50	Q	75.265	0.235	100
12:17:49	Q	75.27	0.24	100
12:17:49	Q	75.27	0.24	1
12:17:49	Q	75.27	0.24	300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-04-25 02:00	U:AZN	News Release200	Q1 2024 results
2024-04-16 07:00	U:AZN	News Release200	IMFINZI(TM) (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
2024-04-11 07:00	U:AZN	News Release200	FASENRA approved for treatment of children aged 6 to 11 with severe asthma
2024-04-05 23:10	U:AZN	News Release200	ENHERTU(TM) Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
2024-04-05 21:43	U:AZN	News Release200	ENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
2024-04-05 07:00	U:AZN	News Release200	IMFINZI(TM) (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
2024-04-02 07:00	U:AZN	News Release200	Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2024-04-01 07:00	U:AZN	News Release200	VOYDEYA(TM) approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Date ET

Symbol

Type

Headline

2024-04-25 02:00

U:AZN

News Release

Q1 2024 results

2024-04-16 07:00

U:AZN

News Release

IMFINZI(TM) (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial